John Valliant
2021
In 2021, John Valliant earned a total compensation of $3.3M as Chief Executive Officer at Fusion Pharmaceuticals, a 53% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $259,699 |
|---|---|
| Option Awards | $2,384,726 |
| Salary | $597,010 |
| Other | $31,332 |
| Total | $3,272,768 |
Valliant received $2.4M in option awards, accounting for 73% of the total pay in 2021.
Valliant also received $259.7K in non-equity incentive plan, $597K in salary and $31.3K in other compensation.
Rankings
In 2021, John Valliant's compensation ranked 4,092nd out of 12,412 executives tracked by ExecPay. In other words, Valliant earned more than 67.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,092 out of 12,412 | 67th |
Division Manufacturing | 1,687 out of 5,498 | 69th |
Major group Chemicals And Allied Products | 697 out of 2,374 | 71st |
Industry group Drugs | 620 out of 2,095 | 70th |
Industry Biological Products, Except Diagnostic Substances | 163 out of 452 | 64th |
Source: SEC filing on April 29, 2022.
Valliant's colleagues
We found two more compensation records of executives who worked with John Valliant at Fusion Pharmaceuticals in 2021.